Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504141 | 0.94 | — | — | |
| SCHEMBL504708 | 0.93 | AGTR1 (0.42) | AGTR1 | |
| SCHEMBL504197 | 0.92 | AGTR1 (0.42) | AGTR1 | |
| SCHEMBL503917 | 0.92 | PPARG (0.42) | AGTR1 | |
| SCHEMBL504700 | 0.90 | AGTR1 (0.40) | AGTR1 | |
| SCHEMBL504703 | 0.90 | AGTR1 (0.41) | AGTR1 | |
| SCHEMBL504245 | 0.89 | — | — | |
| SCHEMBL504742 | 0.89 | AGTR1 (0.41) | AGTR1 | |
| SCHEMBL504246 | 0.88 | — | — | |
| SCHEMBL503893 | 0.88 | AGTR1 (0.42) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664226-B2 | Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same | KOWA COMPANY, LTD. (JP) | 2014-03-04 | — | — | US | claimed |
| EP-2420501-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-02-22 | — | — | EP | claimed |
| US-8664226-B2 | Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same | KOWA COMPANY, LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8664226-B2 | Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same | KOWA COMPANY, LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8664226-B2 | Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same | KOWA COMPANY, LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| EP-2420501-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120028983-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120028983-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120028983-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028983-A1 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME | AGTR2, AGTR1, GPR119 | AGTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.